AMAG Pharmaceuticals, Inc. v. American Guarantee and Liability Insurance Company

CourtDistrict Court, D. Massachusetts
DecidedNovember 15, 2022
Docket1:21-cv-10618
StatusUnknown

This text of AMAG Pharmaceuticals, Inc. v. American Guarantee and Liability Insurance Company (AMAG Pharmaceuticals, Inc. v. American Guarantee and Liability Insurance Company) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
AMAG Pharmaceuticals, Inc. v. American Guarantee and Liability Insurance Company, (D. Mass. 2022).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

) AMAG PHARMACEUTICALS, INC. ) ) Plaintiff, ) ) v. ) Civil Action No. 21-CV-10618-LTS ) AMERICAN GUARANTEE AND ) LIABILITY INSURANCE COMPANY, ) ) Defendant. ) )

ORDER ON CROSS MOTIONS TO COMPEL

LEVENSON, M.J. Plaintiff AMAG Pharmaceuticals, Inc. (“AMAG”) has served a Motion to Compel Discovery upon Defendant American Guarantee and Liability Insurance Company (“Zurich”) (Docket No. 54), and Zurich has served a Motion to Compel upon AMAG (Docket No. 56). The Court has conducted a hearing on both motions. The Court heard argument from the parties on October 11, 2022, and at that time outlined the contours of its rulings on the parties’ respective motions. This written order details those rulings. For the reasons stated below, the Court allows AMAG’s Motion to Compel in part and denies it in part, and allows Zurich’s Motion to Compel in part and denies it in part. I. Background In its Complaint, AMAG alleges breach of contract against Zurich arising from Zurich’s denial of AMAG’s insurance claim in September 2018 under a broad all-risk insurance policy for commercial property and business interruption (the “Policy”).1 Complaint, Docket No. 1-4, ¶¶ 69-76. AMAG made a claim for business losses following an incident at a facility operated by a company (“Supplier”) that manufactures AMAG’s drug product. That damage occurred in November 2017. Although there are disputes about the precise nature of the incident, it involved

some kind of leak or discharge from an air hose and, as a result, a possibility of contamination. Thereafter, Supplier failed to deliver four lots of AMAG’s product. AMAG claims that it suffered tens of millions of dollars of losses and was forced to exit the market. Id., ¶¶ 6, 7. AMAG seeks damages and a declaratory judgment. Id., ¶¶ A-F. II. The Present Motions i. AMAG’s Motion AMAG’s Motion to Compel seeks additional document production in three areas: (1) Zurich’s entire claims file and various documents relating to claims adjustment and handling, including manuals, forms, instructions, guidelines, policies, drafting history, practices and procedures (e.g., Request Nos. 3, 5, and 11);

(2) documents relating to Zurich’s financial reserves in connection with AMAG’s claim (e.g., Request No. 9); and (3) documents relating to Zurich’s insurance of AMAG from the inception of coverage (in other words, documents before the specific policy year in which the contested claim was made). These include initial and renewal policies, underwriting files, loss control and risk

1 The Policy provides coverage for property damage, business interruption (referred to in the Policy as “Time Element”) and contingent business interruption, among other covered causes and types of loss. Specifically, the Policy “[i]nsures against direct physical loss of or damage caused by a Covered Cause of Loss to Covered Property, at an Insured Location[.]” Zurich Policy, Exhibit A, Docket No. 1-1, Policy § 1.01. assessment documents, and documents concerning past claims by AMAG (e.g., Request Nos. 1, 2, 4, and 19). ii. Zurich’s Motion Zurich’s Motion to Compel seeks supplementary responses to discovery requests in three areas:

(1) Interrogatories Nos. 5, 6, 7, 9, 14-18, relating to the rejection or non-delivery of the four lots, direct physical loss or damage to Supplier’s property, the presence of mold at the Facility, AMAG’s slowdown of business activities, damages, and mitigation of losses; (2) Document Requests Nos. 45-47, relating to AMAG’s contentions that certain policy exclusions do not apply to this case; and (3) Requests for Admission Nos. 1, 2, 5, 8, and 11, relating to specific information about failures of the particular components of the Supplier’s equipment and the presence of mold under the equipment. III. Operative Legal Principles

In civil cases, “it is now beyond dispute that ‘[b]road discovery is a cornerstone of the litigation process contemplated by the Federal Rules of Civil Procedure.’” Zubulake v. UBS Warburg, 217 F.R.D. 309, 311 (S.D.N.Y. 2003) (alteration in original). Rule 26 of the Federal Rules of Civil Procedure defines the general scope of discovery as follows: Parties may obtain discovery regarding any nonprivileged matter that is relevant to any party’s claim or defense and proportional to the needs of the case, considering the importance of the issues at stake in the action, the amount in controversy, the parties’ relative access to relevant information, the parties’ resources, the importance of the discovery in resolving the issues, and whether the burden or expense of the proposed discovery outweighs its likely benefit. Information within this scope of discovery need not be admissible in evidence to be discoverable.

Fed. R. Civ. Pro. 26(b)(1) (emphasis added). Rule 26(b)(1) generally permits liberal discovery of relevant information. Baker v. Liggett Group, Inc., 132 F.R.D. 123, 125 (D. Mass. 1990). As the Supreme Court has instructed, because “discovery itself is designed to help define and clarify the issues,” the limits set forth in Rule 26 must be “construed broadly to encompass any matter that bears on, or that reasonably could lead to other matters that could bear on, any issue that is or may be in the case.” Oppenheimer Fund, Inc. v. Sanders, 437 U.S. 340, 351 (1978). Pursuant to Rule 26, the court must limit discovery if it determines that “(i) the discovery sought is unreasonably cumulative or duplicative, or can be obtained from some other source that is more convenient, less burdensome, or less expensive; (ii) the party seeking discovery has had

ample opportunity to obtain the information by discovery in the action; or (iii) the proposed discovery is outside the scope permitted by Rule 26(b)(1).” See Fed. R. Civ. P. 26(b)(2)(C). “The party resisting discovery bears ‘the burden of showing some sufficient reason why discovery should not be allowed.’” HealthEdge Software, Inc. v. Sharp Health Plan, No. 19- CV-11020-ADB, 2021 WL 1821358, at *2 (D. Mass. May 6, 2021) (quoting Flag Fables, Inc. v. Jean Ann’s Country Flags & Crafts, Inc., 730 F. Supp. 1165, 1186 (D. Mass. 1989)). As noted, below, Zurich declined to produce some documents based upon an assertion that the documents in question constituted protected attorney work product. The work product doctrine protects (1) documents or other things, (2) prepared in anticipation of litigation, (3) by or for a party or a party's representative. Fed. R. Civ. P. 26(b)(3); Hickman v. Taylor, 329 U.S.

495 (1947). The party who asserts the work product doctrine “bears the burden of proving not only that the work product doctrine applies to the documents listed in the privilege log but also that any privilege has not been waived.” Woods Hole Oceanographic Institution v. ATS Specialized, Inc., No. 17-CV-12301-NMG, 2020 WL 9743702, at *1 (D. Mass. Oct. 9, 2020); Amgen, Inc. v. Hoecsht Marion Roussel, 190 F.R.D. 287, 289 (D. Mass. 2000). IV. Findings and Orders on AMAG’s Motion to Compel A. The Claims File and Documents Concerning Claims Adjustment and Handling, including Manuals, Forms, Instructions, Guidelines, Policies, Drafting History, Practices and Procedures

AMAG's Request No. 3 seeks Zurich’s entire claims file concerning the AMAG claim.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hickman v. Taylor
329 U.S. 495 (Supreme Court, 1947)
Oppenheimer Fund, Inc. v. Sanders
437 U.S. 340 (Supreme Court, 1978)
Phinney v. Wentworth Douglas Hospital
199 F.3d 1 (First Circuit, 1999)
Flag Fables, Inc. v. Jean Ann's Country Flags & Crafts, Inc.
730 F. Supp. 1165 (D. Massachusetts, 1990)
Russo v. Baxter Healthcare Corp.
51 F. Supp. 2d 70 (D. Rhode Island, 1999)
Amgen Inc. v. Hoechst Marion Roussel, Inc.
190 F.R.D. 287 (D. Massachusetts, 2000)
Zubulake v. UBS Warburg LLC
217 F.R.D. 309 (S.D. New York, 2003)
Baker v. Liggett Group, Inc.
132 F.R.D. 123 (D. Massachusetts, 1990)

Cite This Page — Counsel Stack

Bluebook (online)
AMAG Pharmaceuticals, Inc. v. American Guarantee and Liability Insurance Company, Counsel Stack Legal Research, https://law.counselstack.com/opinion/amag-pharmaceuticals-inc-v-american-guarantee-and-liability-insurance-mad-2022.